A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL
Status:
Active, not recruiting
Trial end date:
2024-03-14
Target enrollment:
Participant gender:
Summary
The design of a phase I, open label, dose finding study was chosen in order to establish a
safe and tolerated dose of single agent ABL001 in CML and Ph+ ALL patients who are relapsed
or refractory to or are intolerant of TKIs, and of ABL001+Nilotinib, ABL001+Imatinib and
ABL001+Dasatinib in Ph positive CML patients who are relapsed or refractory to TKIs.